🔍

Amwill Health Care Ltd (544353)

📊 BSE: 544353 🏢 Pharmaceuticals 📢 Latest filing: 10 Oct 2026

Latest quarterly results (H2 FY26)

In its latest reported quarter, H2 FY26, Amwill Health's revenue was ₹24.0 Cr (+41.2% year on year, +14.3% on the previous half-year), and net profit ₹8.0 Cr (+100.0% year on year); the operating margin was 37.5%.

H2 FY26 (₹ Cr)	Value	YoY vs H2 FY25	vs prev. half
Revenue	₹24.0	+41.2%	+14.3%
Operating profit	₹9.0	+200.0%	+125.0%
Net profit	₹8.0	+100.0%	+100.0%
EPS (₹)	3.77	+79.5%	+95.3%
Operating margin	37.5%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Amwill Health Care Secures CDSCO Approval to Import FoliColor Hair Colour Valid Upto Oct 2031

🟢 POSITIVE ⭐ 5/10

REGULATORY 📅 10 Oct 2026, 01:14 PM

Amwill Health Care has secured a new regulatory licence from the Central Drugs Standard Control Organization (CDSCO) to import FoliColor- Oxidative hair colour (Black variant) into India. The registration certificate (RC/COS- 007631) is valid for five years from October 8, 2026, to October 7, 2031. This approval allows the company to commence import and commercial sales in India, adding to its product portfolio against a backdrop of TTM revenue of ₹85 crore. The counterparty or supplier is confirmed as a non-related party.

CDSCO granted import registration certificate No. RC/COS- 007631 for FoliColor hair colour (Black variant)
Licence valid for 5 years from October 8, 2026, upto October 7, 2031
Approval received by the company on October 9, 2026
Enables commercial import and retail sale in India with an unrelated party supplier

💡 Track the commercial launch timeline and monitor upcoming quarterly filings to see the revenue contribution from the FoliColor line relative to current TTM sales of ₹85 crore.

Amwill Health Care Approves Up to ₹3 Cr Investment in Two SEBI-Registered AIF Schemes

🟡 NEUTRAL ⭐ 3/10

OTHER 📅 25 Sep 2026, 01:43 PM

Amwill Health Care Limited's Investment Committee has approved investments totaling up to ₹3.00 crore across two Alternative Investment Funds (AIFs) from internal accruals. The company will invest up to ₹1.50 crore in units of Vivriti Vihaan Trust and up to ₹1.50 crore in Neo Income Plus Fund III. The total investment of ₹3 crore represents approximately 3.5% of the company's TTM revenue of ₹85 crore and 3.7% of its net worth of ₹81 crore. The transaction does not involve any related parties and is scheduled to be deployed in the ensuing months.

Approval to invest up to INR 1,50,00,000 in Vivriti Vihaan Trust (SEBI-registered AIF)
Approval to invest up to INR 1,50,00,000 in Neo Income Plus Fund III (Neo Credit Alternatives Investment Trust)
Total investment of up to ₹3.00 crore to be funded fully via internal accruals
Confirmed zero related-party involvement in the investment transactions

💡 Track treasury yield disclosures and cash flow deployment in subsequent quarterly financial statements to evaluate returns generated from these fund investments.

Amwill Health Care Approves 5-Year Re-Appointment of Managing Directors Tarun & Anand Gandhi

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 14 Aug 2026, 06:50 PM

Amwill Health Care Limited announced that its shareholders at the 9th Annual General Meeting approved the re-appointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors. The re-appointments are for a period of 5 consecutive years commencing January 27, 2027, through January 26, 2032. Both executives possess over a decade of experience across financial management and dermatology brand marketing. The decision ensures leadership continuity for the company, which reported TTM revenue of Rs 85 Cr and TTM PAT of Rs 23 Cr.

Shareholders approved 5-year re-appointment of Managing Directors at the 9th AGM on August 14, 2026
Term for Mr. Tarun Gandhi (DIN: 07854699) runs from January 27, 2027 to January 26, 2032
Term for Mr. Anand Gandhi (DIN: 07854706) runs from January 27, 2027 to January 26, 2032
Both directors are Key Managerial Personnel and not liable to retire by rotation

💡 Monitor upcoming quarterly operational performance and execution on dermatological segment growth under continuing leadership.

₹33 Cr Investment Limits Approved for Multi-Asset Treasury Strategy

🟡 NEUTRAL ⭐ 5/10

OTHER 📅 08 Aug 2026, 01:31 PM

Amwill Health Care has approved a new hybrid treasury strategy to deploy surplus cash from internal accruals into a multi-asset framework. The company has set aggregate limits totaling ₹33 crore across various asset classes, including debt, equity, and alternative investments. This total limit represents approximately 40.7% of the company's current net worth of ₹81 crore. The strategy aims to optimize post-tax, risk-adjusted returns while maintaining a base in traditional fixed deposits.

Total investment limit of ₹33 crore approved across five distinct financial segments using internal accruals
Allocation of up to ₹15 crore (18.5% of Net Worth) for Private Credit Funds, AIFs, and Structured Debt
Limit of ₹2 crore set for investments in listed equity shares and both Mainboard and SME IPOs
Debt instruments including G-Secs, NCDs, and Commercial Papers capped at an aggregate of ₹10 crore
Additional ₹3 crore limits each for Mutual Fund SIPs and invoice discounting platforms

💡 Investors should monitor the 'Other Income' component in future quarterly results to evaluate the performance of this treasury strategy. It is important to watch if the management maintains focus on the core pharmaceutical business (TTM Revenue ₹85 Cr) while managing these financial assets.

Amwill Health Care Re-appoints Managing Directors for 5-Year Terms Through 2032

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 08 Aug 2026, 01:25 PM

Amwill Health Care has approved the re-appointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for a five-year term commencing January 27, 2027. The company, which operates with a TTM revenue of ₹85 Cr and a healthy 29.4% operating margin, is seeking shareholder approval for these roles at its 9th AGM on August 14, 2026. The leadership continuity is significant for a debt-free firm with a net worth of ₹81 Cr and a high ROCE of 21.0%. The record date for voting eligibility is set for August 8, 2026.

Re-appointment of two Managing Directors for a 5-year tenure from January 27, 2027, to January 26, 2032
9th Annual General Meeting (AGM) scheduled for August 14, 2026, via video conferencing
Record date for determining shareholder voting rights fixed as August 8, 2026
Company maintains a debt-free balance sheet with ₹0 Cr debt and ₹81 Cr net worth
TTM PAT stands at ₹23 Cr on a revenue base of ₹85 Cr

💡 Investors should review the AGM notice for specific details on the proposed remuneration for the Managing Directors and monitor the voting results post-August 14, 2026.

₹2 Crore Fixed Deposit Approval with Vysya Co-operative Bank

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 23 Jul 2026, 06:19 PM

Amwill Health Care's Investment Committee has approved placing ₹2 crores into a Fixed Deposit (FD) with Vysya Co-operative Bank (Tumkur), Bangalore. The investment is funded entirely through the company's internal accruals and is intended to support its long-term growth strategy. Given the company's net worth of ₹81 crore and zero debt status, this represents a small treasury allocation of approximately 2.5% of its net worth. The company confirmed that this is not a related-party transaction.

Investment Committee approved a Fixed Deposit of ₹2 Crores on July 23, 2026
Funds are sourced from internal accruals, maintaining the company's zero-debt status
Deposit will be placed with Vysya Co-operative Bank (Tumkur), Bangalore branch
Investment represents approximately 2.47% of the company's ₹81 Crore net worth

💡 Investors should view this as routine treasury management of surplus cash; no specific action is required other than monitoring interest income in future P&L statements.

Amwill Health Care Announces ₹0.50 Dividend and Re-appointment of MDs with ₹1.57 Cr Salary Each

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 22 Jul 2026, 07:45 PM

Amwill Health Care has scheduled its 9th Annual General Meeting (AGM) for August 14, 2026, to approve a final dividend of ₹0.50 per share for FY 2025-26. A key agenda item is the re-appointment of two Managing Directors, Mr. Tarun Gandhi and Mr. Anand Gandhi, for five-year terms starting January 2027. Each MD is proposed to receive a basic salary of up to ₹1.572 Cr per annum, totaling ₹3.144 Cr for both. This combined maximum remuneration represents approximately 13.6% of the company's TTM PAT of ₹23 Cr.

Proposed final dividend of ₹0.50 per equity share of ₹10 face value for FY 2025-26
Re-appointment of two Managing Directors for 5-year terms (2027-2032) with a maximum salary of ₹1.572 Cr each per annum
Combined maximum MD remuneration of ₹3.144 Cr accounts for ~3.7% of TTM Revenue (₹85 Cr)
Cut-off date for dividend and voting eligibility fixed for August 08, 2026
AGM to be held via Video Conferencing on August 14, 2026

💡 Investors should monitor the AGM voting results, specifically the approval of management remuneration, and track if future profit growth justifies the proposed salary levels.

₹0.50 Dividend and 5-Year Re-appointment of Managing Directors at Amwill Health Care

🟡 NEUTRAL ⭐ 5/10

BOARD_MEETING 📅 22 Jul 2026, 07:19 PM

Amwill Health Care has scheduled its 9th Annual General Meeting (AGM) for August 14, 2026. The board has proposed a final dividend of ₹0.50 per equity share (5% of face value) for FY 2025-26. Key agenda items include the re-appointment of promoters Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for five-year terms starting January 2027, with an annual salary cap of ₹1.572 Cr each. The combined MD remuneration of ₹3.14 Cr represents approximately 13.6% of the company's TTM PAT of ₹23 Cr.

Proposed final dividend of ₹0.50 per equity share for the financial year ended March 31, 2026.
Re-appointment of Mr. Tarun Gandhi as Managing Director for a 5-year term (Jan 2027 - Jan 2032) at ₹1.572 Cr per annum.
Re-appointment of Mr. Anand Gandhi as Managing Director for a 5-year term (Jan 2027 - Jan 2032) at ₹1.572 Cr per annum.
Fixed August 8, 2026, as the cut-off date for dividend entitlement and e-voting eligibility.
Remote e-voting period scheduled from August 11 to August 13, 2026.

💡 Investors should note the August 8, 2026 record date for dividend eligibility and monitor the AGM voting results regarding the significant management remuneration levels.

Amwill Health Care Sets Aug 8 Record Date for Dividend; Re-appoints MDs for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 17 Jul 2026, 04:33 PM

Amwill Health Care has fixed August 08, 2026, as the record date for its final dividend for FY 2025-26 and for determining shareholder eligibility for its 9th Annual General Meeting (AGM). The Board has approved the re-appointment of Managing Directors Mr. Tarun Gandhi and Mr. Anand Gandhi for a five-year term effective from January 27, 2027. The 9th AGM is scheduled for August 14, 2026, via video conferencing. Remote e-voting for shareholders will be available from August 11 to August 13, 2026.

Record date for final dividend and AGM voting eligibility fixed for August 08, 2026
Re-appointment of two Managing Directors for a 5-year term from January 27, 2027, to January 26, 2032
9th Annual General Meeting scheduled for August 14, 2026, at 01:00 PM IST
Remote e-voting period set from August 11, 2026 (09:00 AM) to August 13, 2026 (05:00 PM)
Approval of the Annual Report for the financial year 2025-26

💡 Investors should review the Annual Report for FY26 once released to assess the company's performance and dividend quantum before the August 8 record date.

Amwill Health Care Re-appoints MDs for 5-Year Terms; Sets Aug 14 for 9th AGM

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 17 Jul 2026, 04:29 PM

Amwill Health Care has approved the re-appointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for a five-year term, effective from January 27, 2027, to January 26, 2032. The company has scheduled its 9th Annual General Meeting (AGM) for August 14, 2026, to be held via video conferencing. A record date of August 08, 2026, has been set to determine shareholder eligibility for voting. The board also approved the Annual Report for FY 2025-26, which will be disseminated to shareholders shortly.

Re-appointment of two Managing Directors for a 5-year term starting January 27, 2027.
9th Annual General Meeting (AGM) scheduled for August 14, 2026, at 01:00 p.m.
Record date for AGM voting eligibility fixed as August 08, 2026.
Remote e-voting period set from August 11, 2026 (09:00 AM) to August 13, 2026 (05:00 PM).
Approval of the FY 2025-26 Annual Report and Management Discussion and Analysis Report.

💡 Investors should review the FY26 Annual Report once released to evaluate the company's financial health and management's outlook before the upcoming AGM.

View All 544353 Announcements on Live Market Tracking →